Novel and emerging therapies for B cell lymphoma

Table 4 Small molecule inhibitors

Drug	Class	Patient population	N	ORR	CR	Grade 3 AE	Reference
M7583	BTK inhibitor	R/R DLBCL, WM, MCL, MZL, SLL	18	50%	11%	Diarrhea	[80]
ME-401	PI3Kδ	R/R FL, CLL	31	83%	NA	Diarrhea, rash	[81]
LAM-002A	Endosomal protein inhibitor	R/R DLBCL, MCL, FL, MZL, CLL	24	NA	NA	Tumor lysis syndrome	[82]
INCB057643	BET protein inhibitor	R/R FL, DLBCL	5	33% (DE)	None	Hyperglycemia, thrombocytopenia, anemia, hyperbilirubinemia, Increased INR	[83]
MRG-106	miR-155 inhibitor	Mycosis fungoides	38	NA	NA	Pruritus, tumor flare	[84]
DS-3201b	EZH1/2 dual inhibitor	PTL, AITL, DLBCL, FL, MZL	15	53%	6.6%	Pneumonia	[85]
Apatinib	VEGFR-2 tyrosine kinase inhibitor	R/R NHL	21	47.6%	9.5%	None	[86]

Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, AE adverse events, R/R relapsed and refractory, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MZL marginal zone lymphoma, MCL mantle cell lymphoma, PTL peripheral T cell lymphoma, AITL angio-immunoblastic T cell lymphoma, NHL non-Hodgkin lymphoma, VEGFR-2 vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, PI3Kδ phosphatidylinositol 3 kinase delta, BET bromodomain and extraterminal protein inhibitor, EZH enhancer of zeste homolog, miR micro RN, DE dose escalation phase, NA data unavailable

ISSN: 1756-8722